Beta-Thalassaemia Intermedia : Evaluation of Endocrine and Bone Complications

Abstract EN

Objective.

Data about endocrine and bone disease in nontransfusion-dependent thalassaemia (NTDT) is scanty.

The aim of our study was to evaluate these complications in β-TI adult patients.

Methods.

We studied retrospectively 70 β-TI patients with mean followup of 20 years.

Data recorded included age, gender, haemoglobin and ferritin levels, biochemical and endocrine tests, liver iron concentration (LIC) from T2*, transfusion regimen, iron chelation, hydroxyurea, splenectomy, and bone mineralization by dual X-ray absorptiometry.

Results.

Thirty-seven (53%) males and 33 (47%) females were studied, with mean age 41±12 years, mean haemoglobin 9.2±1.5 g/dL, median ferritin 537 (range 14–4893), and mean LIC 7.6±6.4 mg Fe/g dw.

Thirty-three patients (47%) had been transfused, occasionally (24/33; 73%) or regularly (9/33; 27%); 37/70 (53%) had never been transfused; 34/70 patients had been splenectomized (49%); 39 (56%) were on chelation therapy; and 11 (16%) were on hydroxyurea.

Endocrinopathies were found in 15 patients (21%): 10 hypothyroidism, 3 hypogonadism, 2 impaired glucose tolerance (IGT), and one diabetes.

Bone disease was observed in 53/70 (76%) patients, osteoporosis in 26/53 (49%), and osteopenia in 27/53 (51%).

Discussion and Conclusions.

Bone disease was found in most patients in our study, while endocrinopathies were highly uncommon, especially hypogonadism.

We speculate that low iron burden may protect against endocrinopathy development.